Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Friends, family, and former teammates will gather on Saturday, Aug. 16, 2025, to honor the life and legacy of Steve Huff, a ...

Updated guidance offers evidence-based strategies to optimize the diagnosis and treatment of non-metastatic upper tract ...

Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...

Metastatic prostate cancer is a type of cancer that began in the prostate gland and has spread to other areas of the body, ...

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

The enfortumab Breakthrough designation has come just days after Johnson & Johnson gained the same status for its pipeline drug in metastatic urothelial carcinoma.

Second-look TURBT showed limited value in altering outcomes for high-grade Ta bladder cancer after complete resection.